Risk of Death in Patients With Coronary Artery Disease Taking Nitrates and Phosphodiesterase-5 Inhibitors
- PMID: 38233015
- DOI: 10.1016/j.jacc.2023.10.041
Risk of Death in Patients With Coronary Artery Disease Taking Nitrates and Phosphodiesterase-5 Inhibitors
Abstract
Background: Phosphodiesterase-5 inhibitor (PDE5i) treatment for erectile dysfunction is associated with lower mortality compared with no treatment for erectile dysfunction after myocardial infarction (MI). There are conflicting results regarding the impact of PDE5i treatment on mortality in conjunction with nitrate medication.
Objectives: The purpose of this study was to investigate the association between PDE5i treatment and cardiovascular outcomes in men with stable coronary artery disease treated with nitrate medication.
Methods: Using the Swedish Patient Register and the Prescribed Drug Register we included men with previous MI or revascularization in 2006-2013 who had 2 dispensed nitrate prescriptions within 6 months. Exposure was defined as at least 2 filled prescriptions of any PDE5i. We performed multivariable Cox proportional hazard regression to estimate HRs with 95% CIs for all-cause, cardiovascular, and noncardiovascular mortality, MI, heart failure, cardiac revascularization, and major cardiovascular events (MACE).
Results: In total, 55,777 men were treated with nitrates and 5,710 men with nitrates and a PDE5i. The combined use of PDE5i treatment with nitrates was associated with higher mortality (HR: 1.39; 95% CI: 1.28-1.51), cardiovascular mortality (HR: 1.34; 95% CI: 1.11-1.62), noncardiovascular mortality (HR: 1.40; 95% CI: 1.27-1.54), MI (HR: 1.72; 95% CI: 1.55-1.90), heart failure (HR: 1.67; 95% CI: 1.48-1.90), cardiac revascularization (HR: 1.95; 95% CI: 1.78-2.13), and MACE (HR: 1.70; 95% CI: 1.58-1.83).
Conclusions: The use of a PDE5i in combination with nitrate medication in men with stable coronary artery disease may pose an increased hazard for cardiovascular morbidity and mortality. Careful patient-centered consideration before prescribing PDE5is to patients with cardiovascular disease using nitrate medication is warranted.
Keywords: cardiovascular diseases; erectile dysfunction; mortality; myocardial infarction; sildenafil; tadalafil.
Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Funding Support and Author Disclosures Dr Trolle Lagerros was funded by the Stockholm County Council (clinical research appointment). Dr Andersson was funded by the Stockholm County Council (no. 954970, 963296, 962029), CIMED, and the Strategic Research Program at Karolinska Institutet (no. 961507). None of the funders were involved in the design, conduct of the study, data collection, data analysis, interpretation of data, or preparation, review, or approval of the manuscript. Dr Andersson has received nonfinancial support from COVIS Pharma (study drug donation) as principal investigator in another study; is site principal investigator for Ionis 678354 for Ionis Pharmaceuticals; and is employed at Werlabs; none of these studies or the outside employment are related to the present work. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Comment in
-
Erectile Dysfunction and Coronary Artery Disease: Unfortunate Bedfellows.J Am Coll Cardiol. 2024 Jan 23;83(3):427-429. doi: 10.1016/j.jacc.2023.10.042. J Am Coll Cardiol. 2024. PMID: 38233016 No abstract available.
-
Nitrates and Phosphodiesterase-5 Inhibitors: Something's Gotta Give or Maybe Not?J Am Coll Cardiol. 2024 Jun 11;83(23):e227-e228. doi: 10.1016/j.jacc.2024.03.422. J Am Coll Cardiol. 2024. PMID: 38839206 No abstract available.
Similar articles
-
Association of Phosphodiesterase-5 Inhibitors Versus Alprostadil With Survival in Men With Coronary Artery Disease.J Am Coll Cardiol. 2021 Mar 30;77(12):1535-1550. doi: 10.1016/j.jacc.2021.01.045. J Am Coll Cardiol. 2021. PMID: 33766260
-
Cardiovascular Outcome Risks in Patients With Erectile Dysfunction Co-Prescribed a Phosphodiesterase Type 5 Inhibitor (PDE5i) and a Nitrate: A Retrospective Observational Study Using Electronic Health Record Data in the United States.J Sex Med. 2021 Sep;18(9):1511-1523. doi: 10.1016/j.jsxm.2021.06.010. Epub 2021 Aug 11. J Sex Med. 2021. PMID: 34389264
-
Effect of phosphodiesterase type 5 inhibitors on major adverse cardiovascular events and overall mortality in a large nationwide cohort of men with erectile dysfunction and cardiovascular risk factors: A retrospective, observational study based on healthcare claims and national death index data.J Sex Med. 2023 Jan 14;20(1):38-48. doi: 10.1093/jsxmed/qdac005. J Sex Med. 2023. PMID: 36897243
-
[Sex, erectile dysfunction, and the heart: a growing problem].Herz. 2003 Jun;28(4):284-90. doi: 10.1007/s00059-003-2478-8. Herz. 2003. PMID: 12825143 Review. German.
-
A New Perspective on the Nitrate-Phosphodiesterase Type 5 Inhibitor Interaction.J Cardiovasc Pharmacol Ther. 2018 Sep;23(5):375-386. doi: 10.1177/1074248418771896. Epub 2018 May 8. J Cardiovasc Pharmacol Ther. 2018. PMID: 29739235 Review.
Cited by
-
Long-term effects of phosphodiesterase-5 inhibitors on cardiovascular outcomes and death: a systematic review and meta-analysis.Eur Heart J Cardiovasc Pharmacother. 2024 Aug 14;10(5):403-412. doi: 10.1093/ehjcvp/pvae029. Eur Heart J Cardiovasc Pharmacother. 2024. PMID: 38777751 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
